The comparison of CD4+CAR-T and CD8+CAR-T cells and their anti-tumor activities, as shown by [8] may improve the design and manufacture of a next-generation CAR-T cell with higher anti-cancer efficacy. The gene discussed is CD8A; the disease is neoplasm.